Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | CHUK | O15111 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2537652 | 0.82 | AHR (0.50) | TNFRIPK1GPR84AHRSLC6A2 | |
| Tert-Butyl Formate SCHEMBL28806846 | 0.81 | TDP1 (0.37) | TNFRIPK1GPR84SLC6A2SLC6A4 | |
| SCHEMBL30391792 | 0.77 | AHR (0.45) | TNFRIPK1GPR84AHRSLC6A2 | |
| SCHEMBL1394068 | 0.77 | TNF (0.42) | TNFRIPK1GPR84AHRSLC6A2 | |
| SCHEMBL3961345 | 0.77 | TNF (0.42) | TNFRIPK1GPR84AHRSLC6A2 | |
| SCHEMBL120501 | 0.77 | AHR (0.45) | TNFRIPK1GPR84AHRSLC6A2 | |
| SCHEMBL1960195 | 0.77 | USP2 (0.45) | TNFRIPK1GPR84AHRSLC6A2 | |
| SCHEMBL14909105 | 0.77 | TNF (0.57) | TNFRIPK1GPR84AHRSLC6A2 | |
| Bicarbonate SCHEMBL6221914 | 0.74 | CYP2D6 (0.43) | TNFRIPK1GPR84AHRSLC6A2 | |
| SCHEMBL16629544 | 0.74 | TNF (0.40) | TNFRIPK1GPR84AHRSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115872916-B | Method for synthesizing indole-5-formaldehyde compound based on micro-channel reactor | 华东理工大学 | 2025-03-25 | — | — | CN | disclosed |
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-115872916-A | Method for synthesizing indole-5-formaldehyde compound based on microchannel reactor | 华东理工大学 | 2023-03-31 | — | — | CN | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9399646-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9000175-B2 | Bicyclic GPR119 modulators | LUPIN LIMITED (IN) | 2015-04-07 | — | — | US | disclosed |
| EP-2735562-B1 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2735562-A1 | Estrogen receptor modulators and uses thereof | Seragon Pharmaceuticals, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| EP-2643311-A1 | BICYCLIC GPR119 MODULATORS | Lupin Limited (IN) | 2013-10-02 | — | — | EP | disclosed |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2013-09-19 | — | — | US | disclosed |
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2616445-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| CN-103189361-A | Estrogen receptor modulators and use thereof | ARAGON PHARMACEUTICALS INC | 2013-07-03 | — | — | CN | disclosed |
| WO-2012069917-A1 | BICYCLIC GPR119 MODULATORS | LUPIN LIMITED (IN) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012037411-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | TNF 3856/4885RIPK1 3358/4885GPR84 110/4885 |
| US-20130245000-A1 | BICYCLIC GPR119 MODULATORS | GPR119, GPR180, GPBAR1 | TNF 3232/4885RIPK1 2610/4885GPR84 6/4885 |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | TNF 3858/4885RIPK1 3320/4885GPR84 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.